I mapped every subscription tier from OpenAI, Anthropic, Google, and Mistral against four questions a pharma board needs answered before any AI procurement decision. The result is sobering. 𝗧𝗵𝗲 𝟰 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀: 𝟭. Does the provider train on our inputs by default? 𝟮. Can we lawfully process EU personal data on this tier (GDPR)? 𝟯. Can we lawfully process US patient data on this tier (HIPAA)? 𝟰. Is DPA + BAA + Zero Data Retention available on the same tier? 𝗧𝗵𝗲

A pharma client recently told me: "We moved to AWS European Sovereign Cloud. We are GDPR-safe now." I asked one question: "Who owns the parent company?" Silence. Here is what most people miss: no US hyperscaler sovereign cloud fully eliminates CLOUD Act exposure as of May 2026. Not AWS ESC. Not Microsoft Bleu or Delos. Not Google T-Systems. The European Commission's Cloud Sovereignty Framework, the EDPB, and the French Senate (where US providers conceded they cannot guarantee

When my nine year old builds with LEGO, she checks if she has all the pieces first. Most companies skip that step with agentic AI. They buy the box, open it, and realize half the pieces are missing. Gartner predicts over 40% of agentic AI projects will be cancelled by 2027. Not because the technology fails. Because the organization around it does. 𝗧𝗵𝗲 𝗱𝗶𝗿𝘁𝘆 𝘀𝗲𝗰𝗿𝗲𝘁? Agentic AI does not fail in the algorithm. It fails in five places most companies never check. 𝟭.

I used to think AI strategy was a technology problem. Better tools, faster models, more data. Then I looked at the research: McKinsey, BCG, Deloitte, plus systematic reviews from academia. They all say the same thing. 𝟳𝟬% 𝗼𝗳 𝗔𝗜 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗰𝗼𝗺𝗲𝘀 𝗳𝗿𝗼𝗺 𝗽𝗲𝗼𝗽𝗹𝗲, 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀, 𝗮𝗻𝗱 𝗰𝘂𝗹𝘁𝘂𝗿𝗲. Not algorithms. (BCG, 2024) So what remains when technology is no longer the bottleneck? Leadership. Not the kind that approves budgets and greenlights pi